Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens

30 Dec 2024

Abstract excerpt

BACKGROUND: Doravirine is licensed in patients living with HIV (PWH) harbouring no prior resistance to any NNRTIs. We aimed to evaluate in real life the efficacy of doravirine with prior NNRTI virological failure and NNRTI resistance-associated mutations (RAMs). METHODS: This observational study included PWH switched to a doravirine-containing regimen between 30 September 2019 and 1 May 2022, with an HIV-1 RNA of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV-related health complications and treatments
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39811907
DOI: 10.1093/jac/dkae481

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimensPMID 39811907Read ↗

Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV.Semantic proximity Read ↗

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.Semantic proximity Read ↗

Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.Semantic proximity Read ↗

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.Semantic proximity Read ↗

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.Semantic proximity Read ↗

Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug ResistanceSemantic proximity Read ↗

Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.Semantic proximity Read ↗

Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.Semantic proximity Read ↗

Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.Semantic proximity Read ↗

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.Semantic proximity Read ↗

Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.Semantic proximity Read ↗

Emerging reverse transcriptase inhibitors for HIV-1 infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.